Harris et al reported the TRAIL model for evaluating a patient with diffuse large B-cell lymphoma (DLBCL). This can predict the tolerability of immunochemotherapy for the patient. The authors are from Genentech, Imperial College Healthcare NHS Trust, Aalborg University Hospital and Hoffmann-La Roche.

Patient selection: diffuse large B-cell lymphoma


Immunochemotherapy: CHOP with rituximab or obinutuzumab



(1) creatinine clearance in mL per min

(2) serum albumin in g/L

(3) Charlson Comorbidity Index (CCI)

(4) history of heart disease, vascular disease or diabetes




creatinine clearance

86.8 * (1 / (creatinine clearance))

serum albumin

-2.48 * LN(albumin)

Charlson Comorbidity Index

0.170 * (CCI)


0.362 if present; 0 if absent


value of X =

= SUM(points for all of the parameters) + 5.45


probability of being unable to tolerate CHOP in combination with ritixumab or obinutuzumab =

= 1 / (1 + EXP((-1) * X))

To read more or access our algorithms and calculators, please log in or register.